Home

Breaking drug resistance in cancer through the development of a new class of therapies that target key drivers of ongoing DNA mutation and tumor evolution.

In the Press

Accelerator Corporation Announces $7M Series A Investment in ApoGen Biotechnologies to Develop a New Class of Drugs Targeting Resistance to Cancer Therapy

Click Here

ApoGen Biotechnologies Raises $7 Million Series A

(Wall Street Journal Online)

ApoGen Biotech Lands $7M to Take On Drug Resistance in Cancer

(Xconomy.com)